The W.M. Keck Biomedical Mass Spectrometry Lab is dedicated to providing access to state of the art mass Spectrometry instrumentation and highly trained personnel. The facility currently has a time-of-flight mass spectrometer (ABI Voyager DE-Pro) equipped with a MALDI source (MALDI-TOF) for high accuracy mass measurement of peptides and small molecules as well as detection of intact proteins up to ~150 kDa. In addition, one ion trap and one hybrid ion trap-FTICR each equipped with microspray sources (Thermo Electron LCQ DecaXP and LTQ-FT) provide detailed information on proteins such as identification, relative quantitation, and post-translational modification discovery. In particular, the FTICR is capable of high resolution/mass accuracy at ultra-high sensitivity. For larger numbers of samples, the facility has 96-well format automated equipment such as the Genomic Solutions ProGest (sample digestion) and the Genomic Solutions ProMS (sample processing for peptide mass fingerprinting). The critical mission of the facility is to provide Cancer Center investigators with expertise in pre-experiment planning, data acquisition, and data interpretation for a wide variety of experimental questions ranging from basic science to clinical applications. This 'start to finish'guidance provides investigators with interactions critical to experimental success and is not often found at other facilities. Lab personnel also give periodic lectures to the university community to keep investigators apprized of currently available instrumentation and techniques and to keep themselves current on the types of questions Cancer Center members would like to address in their research.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA044579-20
Application #
8104151
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2010-02-01
Budget End
2011-01-31
Support Year
20
Fiscal Year
2010
Total Cost
$91,577
Indirect Cost
Name
University of Virginia
Department
Type
DUNS #
065391526
City
Charlottesville
State
VA
Country
United States
Zip Code
22904
Wang, T Tiffany; Yang, Jun; Zhang, Yong et al. (2018) IL-2 and IL-15 blockade by BNZ-1, an inhibitor of selective ?-chain cytokines, decreases leukemic T-cell viability. Leukemia :
Yao, Nengliang; Zhu, Xi; Dow, Alan et al. (2018) An exploratory study of networks constructed using access data from an electronic health record. J Interprof Care :1-8
Kiran, Shashi; Dar, Ashraf; Singh, Samarendra K et al. (2018) The Deubiquitinase USP46 Is Essential for Proliferation and Tumor Growth of HPV-Transformed Cancers. Mol Cell 72:823-835.e5
Conaway, Mark R; Petroni, Gina R (2018) The Impact of Early-Phase Trial Design in the Drug Development Process. Clin Cancer Res :
Szlachta, Karol; Kuscu, Cem; Tufan, Turan et al. (2018) CRISPR knockout screening identifies combinatorial drug targets in pancreatic cancer and models cellular drug response. Nat Commun 9:4275
Khalil, Shadi; Delehanty, Lorrie; Grado, Stephen et al. (2018) Iron modulation of erythropoiesis is associated with Scribble-mediated control of the erythropoietin receptor. J Exp Med 215:661-679
Olmez, Inan; Zhang, Ying; Manigat, Laryssa et al. (2018) Combined c-Met/Trk Inhibition Overcomes Resistance to CDK4/6 Inhibitors in Glioblastoma. Cancer Res 78:4360-4369
Parini, Paolo; Melhuish, Tiffany A; Wotton, David et al. (2018) Overexpression of transforming growth factor ? induced factor homeobox 1 represses NPC1L1 and lowers markers of intestinal cholesterol absorption. Atherosclerosis 275:246-255
Banizs, Anna B; Huang, Tao; Nakamoto, Robert K et al. (2018) Endocytosis Pathways of Endothelial Cell Derived Exosomes. Mol Pharm :
Jia, Deshui; Augert, Arnaud; Kim, Dong-Wook et al. (2018) Crebbp Loss Drives Small Cell Lung Cancer and Increases Sensitivity to HDAC Inhibition. Cancer Discov 8:1422-1437

Showing the most recent 10 out of 539 publications